Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $11.9700 (-1.72%) ($11.9400 - $11.9700) on Thu. Dec. 8, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.01% (three month average) | RSI | 69 | Latest Price | $11.9700(-1.72%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.5% a day on average for past five trading days. | Weekly Trend | FOLD advances 5% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(54%) IWO(45%) IWM(44%) IWC(43%) IWN(42%) | Factors Impacting FOLD price | FOLD will decline at least -1.505% in a week (0% probabilities). VIXM(-13%) VXX(-12%) XLU(-8%) TLT(-5%) ARKG(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.505% (StdDev 3.01%) | Hourly BBV | -2.7 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $12.3(-2.68%) | 10 Day Moving Average | $12.06(-0.75%) | 20 Day Moving Average | $11.66(2.66%) | To recent high | -5.9% | To recent low | 19.7% | Market Cap | $3.091b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |